OPKO Health (NASDAQ:OPK) vs. Anteris Technologies Global (NASDAQ:AVR) Financial Analysis

OPKO Health (NASDAQ:OPK) and Anteris Technologies Global (NASDAQ:AVR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings.

Institutional & Insider Ownership

64.6% of OPKO Health shares are held by institutional investors. 49.7% of OPKO Health shares are held by company insiders. Comparatively, 4.0% of Anteris Technologies Global shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for OPKO Health and Anteris Technologies Global, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1	3	2	1	2.43
Anteris Technologies Global	1	0	4	0	2.60

OPKO Health currently has a consensus price target of $2.28, suggesting a potential upside of 67.89%. Anteris Technologies Global has a consensus price target of $16.50, suggesting a potential upside of 267.48%. Given Anteris Technologies Global’s stronger consensus rating and higher probable upside, analysts clearly believe Anteris Technologies Global is more favorable than OPKO Health.

Profitability

This table compares OPKO Health and Anteris Technologies Global’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OPKO Health	-28.10%	-13.62%	-8.59%
Anteris Technologies Global	N/A	N/A	N/A

Earnings & Valuation

This table compares OPKO Health and Anteris Technologies Global”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$642.07 million	1.63	-$53.22 million	($0.25)	-5.44
Anteris Technologies Global	$2.70 million	59.97	-$76.29 million	($1.19)	-3.77

OPKO Health has higher revenue and earnings than Anteris Technologies Global. OPKO Health is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.

Summary

Anteris Technologies Global beats OPKO Health on 8 of the 14 factors compared between the two stocks.

About OPKO Health

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

About Anteris Technologies Global

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.